Bioton to raise zl.300 million from latest share issue

The company did not specify the objective of this transaction, but only informed of "acquisitions and investment objectives, information about which the company will deliver in successive current reports". According to recent announcements by the company's president Adam Wilczega, the firm will designate the funds to boost the production of insulin and intangible assets, such as licenses. Bioton intends to finance taking control over Ukrainian Indar, conclude the construction of its plant in Russia and domestic investments worth about zl.100 million. However, analysts are divided over whether company's shares are not overvalued. (Parkiet, p. 3, Puls Biznesu, p. 14) M.M.